Clinical trial · Interventional
Senescence and the Early Ageing Phenotype After Chemotherapy for Testicular Cancer: the SEA-CAT Study
NCT04113122CI-TRIAL-00083719recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Cisplatin-combination chemotherapy causes inevitably DNA damage by platinum-DNA adduct formation of both tumor cells but also healthy cells. It therefore stands to reason that testicular cancer treatment causes an increased burden of senescent cells, which causes upregulation of the SASP resulting in a pro-inflammatory phenotype. The investigators hypothesize that this may be an important mechanism behind development of late effects and an early ageing phenotype after treatment for testicular cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Testicular Cancer | Malignant Testicular Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Skin biopsy | Diagnostic Test | — | UNRESOLVED |
| Subcutaneous fat biopsy | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Cross-sectional study:
- description
- Testicular cancer survivors who were treated between 2000 and 2005 or between 2006 and 2012 with cisplatin-combination chemotherapy and who were extensively phenotypically mapped within two longitudinal trials (15,16) will be invited to participate in a single cross-sectional follow-up study visit 5-20 years after chemotherapy.
- interventionNames
- Diagnostic Test: Skin biopsy
- Diagnostic Test: Subcutaneous fat biopsy
- type
- EXPERIMENTAL
- label
- Longitudinal study - chemotherapy group
- description
- Patients with metastasized testicular cancer who are about to start with cisplatin-combination chemotherapy will be invited in the longitudinal part of this study. Study participation involves four study visits: Visit 1: before start of chemotherapy Visit 2:before third cycle of chemotherapy Visit 3: one month after completion of chemotherapy Visit 4: one year after start of chemotherapy
- interventionNames
- Diagnostic Test: Skin biopsy
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
- Maximum age
- 50 Years
Show eligibility criteria text
Inclusion Criteria: In order to be eligible to participate in the cross-sectional part of this study, a subject must meet all of the following criteria: * Diagnosed with metastatic testicular cancer in 1999-2012 (stage II or higher) * Received first-line cisplatin-based chemotherapy * Was younger than 50 years of age at start of chemotherapy In order to be eligible to participate in the longitudinal part of this study, a subject must meet all of the following criteria: Chemotherapy-group: * Diagnosis of metastatic testicular cancer (stage II or higher) * Is about to start with first-line cisplatin-based chemotherapy * Younger than 50 years of age at diagnosis of metastatic testicular cancer Stage I control-group: * Diagnosis of testicular cancer stage I disease * Younger than 50 years of age at diagnosis of testicular cancer Exclusion Criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: \- Not able to provide informed consent (in example in case of mental or psychiatric disability)
References
Publications (0)
Data not yet available
No reference posted for this study.